Innovent Biologics rises as regulator approves co's product for cancer treatment

China Renaissance Holdings

17/01/2025 03:41

** Shares of Innovent Biologics Inc  1801.HK  rise 3.3% to
HK$31, on course to snap two consecutive session of decline
    ** Stock on track for the biggest one-day jump since Dec. 9,
2024; among top 10 gainers in healthcare index  .HSCIH , which
is up 0.8%
    ** Innovent says new drug application of limertinib - the
third-generation epidermal growth factor receptor tyrosine
kinase inhibitor, has received approval by National Medical
Products Administration of China (NMPA) for treatment of lung
cancer
    ** Hang Seng Commerce & Industry Index  .HSNC  and Hang Seng
Index  .HSI  boht slip 0.1%
    

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))